The coamplification pattern of the MYCN amplicon is an invariable attribute of most MYCN-amplified human neuroblastomas

Clinical Cancer Research

Volumn 12, Issue 24, 2006, Pages 7316-7321

  Weber, Axel ^a   Starke, Sven ^a   Bergmann, Eckhard ^a   Christiansen, Holger ^a,b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE ANTIBODY; RETINOIC ACID;

ADOLESCENT; AMPLICON; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE STRUCTURE; GENETIC ANALYSIS; HAPLOIDY; HUMAN; HUMAN TISSUE; INFANT; NEUROBLASTOMA; ONCOGENE MYC; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT DISEASE;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; INFANT; INFANT, NEWBORN; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS;

EID: 33846211011     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0837     Document Type: Article

References (26)

1. Schwab M, Alitalo K, Klempnauer KH, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983;305:245-8.
2. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4.
3. Brodeur GM, Maris JM, Yamashiro DJ, Hogarty MD, White PS. Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol 1997;19:93-101.
4. Weber A, Imisch P, Bergmann E, Christiansen H. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma. J Clin Oncol 2004;22:2681-90.
5. De Preter K, Speleman F, Combaret V, et al. No evidence for correlation of DDX1 gene amplification with improved survival probability in patients with MYCN-amplified neuroblastomas. J Clin Oncol 2005;23:3167-8; author reply 3168-70.
6. Squire JA, Thorner PS, Weitzman S, et al. Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma. Oncogene 1995;10:1417-22.
7. George RE, Kenyon R, McGuckin AG, et al. Analysis of candidate gene co-amplification with MYCN in neuroblastoma. Eur J Cancer 1997;33:2037-42.
8. Manohar CF, Salwen HR, Brodeur GM, Conn SL. Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma. Genes Chromosomes Cancer 1995;14:196-203.
9. De Preter K, Speleman F, Combaret V, et al. Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay. Mod Pathol 2002;15:159-66.
10. Hahn P, Nevaldine B, Morgan WF. X-ray induction of methotrexate resistance due to dhfr gene amplification. Somat Cell Mol Genet 1990;16:413-23.
11. Hahn PJ, Nevaldine B, Longo JA. Molecular structure and evolution of double-minute chromosomes in methotrexate-resistant cultured mouse cells. Mol Cell Biol 1992;12:2911-8.
12. Pauletti G, Lai E, Attardi G. Early appearance and long-term persistence of the submicroscopic extrachromosomal elements (amplisomes) containing the amplified DHFR genes in human cell lines. Proc Natl Acad Sci U S A 1990;87:2955-9.
13. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77.
14. Berthold F, Burdach S, Kremens B, et al. The role of chemotherapy in the treatment of children with neuroblastoma stage IV: the GPO (German Pediatric Oncology Society) experience. Klin Padiatr 1990;202:262-9.
15. Berthold F, Hero B. Neuroblastoma: current drug recommendations as part of the total treatment approach. Drugs 2000;59:1261-77.
16. Cheng JM, Hiemstra JL, Schneider SS, et al. Preferential amplification of the paternal allele of the N-myc gene in human neuroblastomas. Nat Genet 1993;4:191-4.
17. London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005;23:6459-65.
18. Hiemstra JL, Schneider SS, Brodeur GM. High-resolution mapping of the N-myc amplicon core domain in neuroblastomas. Prog Clin Biol Res 1994;385:51-7.
19. Brodeur GM, Green AA, Hayes FA, Williams KJ, Williams DL, Tsiatis AA. Cytogenetic features of human neuroblastomas and cell lines. Cancer Res 1981;41:4678-86.
20. Yoshimoto M, Caminada De Toledo SR, et al. MYCN gene amplification. Identification of cell populations containing double minutes and homogeneously staining regions in neuroblastoma tumors. Am J Pathol 1999;155:1439-43.
21. Schneider SS, Hiemstra JL, Zehnbauer BA, et al. Isolation and structural analysis of a 1,2-megabase N-myc amplicon from a human neuroblastoma. Mol Cell Biol 1992;12:5563-70.
22. Pandita A, Godbout R, Zielenska M, Thorner P, Bayani J, Squire JA. Relational mapping of MYCN and DDXI in band 2p24 and analysis of amplicon arrays in double minute chromosomes and homogeneously staining regions by use of free chromatin FISH. Genes Chromosomes Cancer 1997;20:243-52.
23. Hahn Peter J. Molecular biology of double minute chromosomes. Bioessays 1993;15:477-84.
24. Von Hoff DD, McGill JR, Forseth BJ, et al. Elimination of extrachromosomally amplified MYC genes from human tumor cells reduces their tumorigenicity. Proc Natl Acad Sci U S A 1992;89:8165-9.
25. Brodeur GM, Hayes FA, Green AA, et al. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res 1987;47:4248-53.
26. Fulda S, Lutz W, Schwab M, Debatin KM. MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene 1999;18:1479-86.